Active Stocks: Clovis Oncology, CymaBay Therapeutics, Provectus Biopharmaceuticals, Tonix Pharmaceuticals, Seattle Genetics Print E-mail
By Marilyn Mullen   
Monday, 29 September 2014 15:11

Global equity markets fell on filter: progid:DXImageTransform.Microsoft.gradient( startColorstr='#ededed', endColorstr='#cdcdcd',GradientType=0 ); _background: #ededed} Monday as civil unrest in Hong Kong weighed on investor sentiment, while U.S. Treasury debt prices rose over uncertainty sparked by the a{text-decoration:none; outline:none} protests.

Stocks on .content{background:#483d5b; -webkit-box-shadow: 0px -1px 10px 0px rgba(0,0,0,0.75); Wall Street opened sharply lower following declines in Europe and Asia as Hong Kong democracy protesters defied volleys of .arrowsv2{background:url(} tear gas and police baton charges in one of #main-wrap{background:url(} the a:hover{text-indent:0; cursor:pointer; outline:0 none;} biggest political challenges for China since the .clearfix:after{visibility: hidden;display:block;font-size: 0;content: " ";clear: both;height:0} Tiananmen Square crackdown 25 years ago.


Shares of Clovis Oncology Inc. (NASDAQ:CLVS) jump on -moz-box-shadow: 0px -1px 10px 0px rgba(0,0,0,0.75); a 2x surge in volume in response to .srch-txt{float:left; width:242px; height:28px; font-size:16px; line-height:28px; background:url( 7px 5px no-repeat #fff; color:#414141; padding: 0 5px 0 30px; border:1px solid #6f6f6f; outline:none} its presentation of .container{width:960px; margin:0 auto} positive clinical trial results for rucaparib at the * html .clearfix{zoom:1} ESMO Congress in Madrid, Spain today.In the .brradius{border-radius:3px; -moz-border-radius:3px; -ms-border-radius:3px; -o-border-radius:3px; -webkit-border-radius:3px} Phase 2 portion of .header{height:100px; border-top:10px solid #472558; background:url(; overflow:hidden} a Phase 1/2 trial evaluating the *:first-child+html .clearfix{zoom:1} overall response rate, safety and tolerability and duration of .leftblk{float:left; overflow:hidden} response in women with platinum-sensitive relapsed germline BRCA-associated ovarian cancer, patients treated with rucaparib showed a disease control rate (a complete response, partial response or stable disease greater than 12 weeks) of 93% (14/15). In addition, 82% (14/17) achieved a RECIST and/or CA-125 response of .leftblk img{float: left; margin-top:22px; *margin-top:18px; padding-right: 15px;} whom 71% (12/17) achieved a RECIST Partial Response

CymaBay Therapeutics Inc. (NASDAQ:CBAY) completes patient enrollment in its ongoing Phase 2b clinical trial of .domain_name{float:left; line-height:34px; font-size:26px; font-weight: normal; color:#fff; padding-top:27px; width:535px} arhalofenate in patients with gout. The company expects to .srch-btn{float:right; width:66px; height:30px; font-size:13px; color:#303030; border:1px solid #6f6f6f; margin-left:4px; _border:none; * border:none; outlin:none; cursor:pointer; report top-line results in Q2 2015.The study's primary efficacy endpoint is .frt_arr{float:left;width:223px; height:503px; background-position:0 3px; background-repeat:no-repeat} the prevention of #logo{float:right;width:300px;padding:15px 0 0} flares.

At the ESMO Congress in Madrid, Spain, Provectus Biopharmaceuticals Inc. (NYSEMKT:PVCT) presented data from an 80-patient single arm Phase 2 trial evaluating the safety and efficacy of #logo p{text-align:right;clear:both;padding:4px 2px 0 0; color:#aeaeae;} PV-10 over 12 months in patients with locally advanced cutaneous melanoma.

Thinly-traded nano cap Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) craters 44% premaket on box-shadow: 0px -1px 10px 0px rgba(0,0,0,0.75);} robust volume after the body{font:normal 12px Arial, Helvetica, sans-serif; background:url(} company reported top-line results from a 205-patient Phase 2b clinical trial of TNX-102 as a chronic bedtime treatment for fibromyalgia.

Seattle Genetics, Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Co. announce positive results from a 329-patient Phase 3 clinical trial evaluating the safety and efficacy of Adcetris (brentuximab vedotin) as consolidation therapy immediately following an autologous stem cell transplantation (ASCT) in patients with Hodgkin lymphoma (HL). The study met its primary endpoint of #logo p a{color:#ffffff;font-size:11px;text-decoration:underline;} a statistically significant improvement in progression-free survival (PFS) compared to background: #ededed; placebo. PFS improved 75% as assessed after a minimum of #logo img{border:0 none;} two years post initiation of .searchbox{float:right; width:351px; height:30px; padding-top:38px} treatment by an independent central review committee.

BiomedReports is .lst_arr{float:left;width:223px; height:503px; background-position:right 3px; background-repeat:no-repeat} not paid or compensated by newswires to background: -moz-linear-gradient(top, #ededed 0%, #cdcdcd 100%); disseminate or report news and developments about publicly traded companies, but may from time to background: -webkit-gradient(linear, left top, left bottom, color-stop(0%,#ededed), color-stop(100%,#cdcdcd)); time receive compensation for advertising, data, analytics and